Patent intelligence · US
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
Patent details — US 12371435
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 29, 2025
- Expiration
- Jul 24, 2045
- Applicant
- Mirati Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61P, A61P35/00
Quick answer
US 12371435 (Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P35/00
More from Mirati Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted
Frequently asked questions
What is US patent 12371435?
US 12371435 (Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors) is held by Mirati Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12371435?
Mirati Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 12371435 expire?
Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.